SIR-SPHERES MICROSPHERES
Report
- Report Number
- 9710358-2009-00001
- Event Type
- Death
- Date Received
- January 22, 2009
- Report Date
- January 20, 2009
- Manufacturer
- SIRTEX MEDICAL LIMITED
- Product Code
- KXK
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- NJ, US
- Reporter Occupation
- PHYSICIAN
Narratives
PT WAS POLYCHEMOTHERAPY RESISTANT AND TREATED AS SALVAGE THERAPY WHERE THERE IS USUALLY AN EXTREMELY NARROW WINDOW OF NORMAL LIVER. RAISED BILIRUBIN AT 4 WEEKS POST SIRT IS CONSISTENT WITH RADIATION HEPATITIS/RADIATION-INDUCED LIVER DISEASE. WE WILL FOLLOW UP FOR DISCUSSIONS TO REVIEW: DOSIMETRY IN POLYCHEMOTHERAPY-RESISTANT MCRC. MGMT OF RADIATION HEPATITIS/RADIATION INDUCED LIVER DISEASE BASED ON CURRENT LITERATURE. THERE IS NO EVIDENCE OF PRODUCT MALFUNCTION - THE BATCH MET ALL RELEASE CRITERIA. SEE SCANNED PAGE.
DEATH RELATED TO MUTI-ORGAN SYSTEM FAILURE COMPLICATING SEPSIS. ORIGINAL DIAGNOSIS, 2004, LIVER METASTASES. 2004, TREATMENTS INCLUDED: 5 FU, AVASTIN, ERBITUX, IRINOTECAN. ECOG 0. NO UNDERLYING LIVER DISEASE. BSA 1.92 SHUNT 6%. BASELINE LFT. TI BILI 1.5. ERBITUX DISCONTINUED 2 WEEKS PRIOR TO TREATMENT. SIR-SPHERES TREATMENT WHOLE LIVER TREATMENT DATE 2008. LIVER VOL 2178. PRESCRIBED ACT 1.9 GBQ. DELIVERED 1.9 GBQ. ERBITUX REINITIATED AFTER 2 WKS AT ONCOLOGIST. FAILURE TO RESPOND TO MEDICAL TREATMENT OF SEPSIS LED TO MULTIORGAN SYSTEM FAILURE AND DEATH FROM COMPLICATIONS OF SEPSIS ABOUT 3 MONTHS LATER. WHILE THE PATIENT'S RADIATION INDUCED, LIVER DISEASE APPEARED TO RESPOND TO STEROID THERAPY. IT IS FELT THAT THE STEROID THERAPY CONTRIBUTED TO THE PATIENT'S SEPSIS.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 1 | SIR-SPHERES MICROSPHERES | YTTRIUM 90 RESIN MICROSPHERES | KXK | SIRTEX MEDICAL LIMITED | Y001 | 115698-09 OR -09 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 63 YR | Death |